ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

June 24, 2020

For more information: [www.cdc.gov/COVID19](http://www.cdc.gov/COVID19)
COVID-19 vaccination in the United States

Need for equitable access to safe and effective vaccines and evidence-based vaccination policy

- Preparing for implementation of *safe and effective* COVID-19 vaccines is a critical next step to protect the public and reduce the impact of COVID-19 on society.

- Increased risk of severe COVID-19 in vulnerable populations and racial/ethnic minority groups highlight the need for:
  - *Diverse representation* in clinical trials
  - *Equitable access* to vaccines, regardless of vaccination strategy or priority groups

- ACIP COVID-19 vaccines work group established to help inform *evidence-based approaches* to COVID-19 vaccination policy.
ACIP COVID-19 Vaccines Work Group

- **Established**: April 2020

- **Role**: Collection, analysis, and preparation of information related to COVID-19 vaccines for presentation, discussion, deliberation, and vote by the ACIP, using an open and transparent process.

- **Membership**: 41 members, including ACIP voting members, liaisons, *ex-officios*, and expert consultants
Expertise areas of COVID-19 Work Group members

- Epidemiology
- Vaccine safety
- Vaccinology
- Infectious diseases
- Immunology
- General medicine
- Geriatrics
- Pediatrics
- Obstetrics
- Immunocompromised hosts

- Vaccine administration/delivery
- Public health/surveillance
- Ethics
- Health equity
- Communications
- Emergency preparedness
COVID-19 Work Group composition

4 ACIP voting members
Chair
Beth Bell

Consultants
• Vaccinology
• Microbiology/Immunology
• Safety
• Ethics
• Health equity

Liaison representatives

Ex-officio/government members

CDC participants
Co-leads: Kathleen Dooling
Sarah Mbaeyi

CDC experts

National Advisory Committee on Immunization
Policy topic under consideration: Use of COVID-19 vaccines in the U.S. population.

Work Group activities:
- Review safety and immunogenicity data for COVID-19 vaccines
- Review the epidemiology of COVID-19 disease and identify potential target populations for vaccination
- Discuss potential vaccine prioritization plans in the event of insufficient early COVID-19 vaccine supply
- Identify areas where additional data are needed to inform COVID-19 vaccine recommendations
- Develop COVID-19 vaccine policy options that ACIP may consider for recommendation

Vaccine safety technical subgroup: advises the main Work Group on the safety of COVID-19 vaccines, both during clinical development and post-licensure
Decision-making in the context of many unknowns and uncertainties

- Stand for the principles of evidence-based decision-making, equity, and transparency in the process
- Tension between the need to provide guidance and the limited available science base
- Strive to develop a robust understanding of what is known; make sure diverse voices are heard
- Make decisions based on the knowns at the time
- Recognize from the start that revisions will be needed as more information becomes available
- Advocate for implementation of the essential strategies and systems to ensure that pivotal data for decision-making get collected
- Promote a feedback loop to evaluate the impact of recommendations and commit to revising accordingly
Today’s agenda

- COVID-19 vaccine development
  - Dr. Matthew Hepburn (Lead, Operation Warp Speed Vaccines)

- Landscape of COVID-19 vaccines in development
  - Dr. Kathy Neuzil (University of Maryland)

- COVID-19 vaccine prioritization considerations
  - Dr. Sarah Mbaeyi (CDC)

- Work Group considerations and next steps
  - Dr. Kathleen Dooling (CDC)
Work group members

ACIP members
- Beth Bell (chair)
- Grace Lee
- Jose Romero
- Keipp Talbot

Ex-officio/government members
- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Jillian Doss-Walker
- DOD: Eric Deussing
- CMS: Jeff Kelman
- BARDA: Christine Oshansky

CDC Co-leads
- Kathleen Dooling
- Sarah Mbaeyi

Liaisons
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

Liaisons, cont’d
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Althea House (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: David Weber

Consultants
- Ed Belongia (safety)
- Matthew Daley (safety)
- Kathy Kinlaw (ethics)
- Dayna Matthew (health equity)
- Kathleen Neuzil (vaccinology)
- Stanley Perlman (microbiology/immunology)
CDC participants

- Doug Campos-Outcalt
- Thomas Clark
- Amanda Cohn
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Sam Graitcer
- Lisa Grohskopf
- Rita Helfand
- Terri Hyde
- Tara Jatlaoui

- Cynthia Jorgensen
- Jessica MacNeil
- Rebecca Morgan
- Sara Oliver
- Anita Patel
- Stephanie Schrag
- Tom Shimabukuro
- Nathalie Thornburg
- Jennifer Verani
- Cindy Weinbaum
- Yon Yu
- Jane Zucker
For more information, contact CDC
1-800-CDC-INFO (232-4636)

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.